

Special Issue

Molecular Biology in Targeted Radionuclide Therapy Radiopharmaceutical Design

Message from the Guest Editors

Targeted radionuclide therapy (TRT) can be defined by the delivery of radionuclides to a tumor-associated target, which may be present in the tumor cell itself or in the microenvironment. The design of a radiopharmaceutical for TRT requires a multidisciplinary team involving biologist, radio chemist, radio pharmacologist, medical, and physical staff. After conjugation, usually by means of a bifunctional chelator, the compound may lose some affinity for the target. Great efforts have been made to select the more specific ligand and optimal labelling method in order to increase the specificity for the tumor tissue and the residence time to decrease the dose to normal tissues and critical organ subregions. Molecular biology plays a fundamental role also in the field of nanosized particles loaded with radionuclides; specific coating may drive these particles towards the tumor, reducing the RES uptake. Contributing papers to this Special Issue will present recent progress in the molecular approach to TRT of cancer, with emphasis on how to better design a radiopharmaceutical.

Guest Editors

Dr. Carlo Aprile

IRCCS Fondazione Policlinico San Matteo, Nuclear Medicine Unit, I-27100 Pavia, Italy

Dr. Onelio Geatti

Studio di Radiologia Bazzocchi, 34135 Trieste, Italy

Dr. Lorenzo Lodola

IRCCS Fondazione Policlinico San Matteo, Nuclear Medicine Unit, I-27100 Pavia, Italy

Deadline for manuscript submissions

closed (30 November 2022)



Current Issues in Molecular Biology

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 2.9
Indexed in PubMed



mdpi.com/si/103242

Current Issues in Molecular Biology

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cimb@mdpi.com

[mdpi.com/journal/
cimb](https://mdpi.com/journal/cimb)





Current Issues in Molecular Biology

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 2.9
Indexed in PubMed



[mdpi.com/journal/
cimb](https://mdpi.com/journal/cimb)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Madhav Bhatia
Department of Pathology and Biomedical Science, University of Otago,
Christchurch, 2 Riccarton Avenue, P.O. Box 4345, Christchurch 8140,
New Zealand

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PMC, PubMed, Embase, CAPus / SciFinder, FSTA, AGRIS, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.8 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2024).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names are published annually in the journal.